Annexin 2 protein expression is associated with breast cancer subtypes in African American women

Abstract

Background: A review of literature on the expression of Annexin 2 in cancer has shown that there is very limited research work on the association of this protein with breast cancer aggressiveness in African Americans. In the present study, TMA breast tissues from African American women were stained with Annexin 2 antibody to determine the association between the molecular subtypes and Annexin 2 protein expression. Method: An annotated case series of 135 breast cancer tissues archived from 2000 to 2010 was acquired from the Howard University Tumor Registry. The association between ANX2 expression and survival by molecular subtypes Luminal A, Luminal B, HER2, and Triple Negative (TN) was assessed using Multinomial regression, chisquare analysis, and Kaplan-Meir graphs (Stata 11). Results: Our findings show a marked association between ANX2 protein expression in Luminal B and HER2 subtypes unadjusted and when adjusted for age. Borderline differences in tumor grade were found in TN only. Univariately, age (<50, 50 þ years) and metastases were highly significant for overall survival, disease-free survival and recurrence-free survival. Stage, tumor size, and nodal involvement were of borderline or greater significance for overall and disease-free survival. ANX2 expression was not significant. Kaplan Meier tests of ANX2 showed significant separation of overall survival by ANX2 protein expression in all breast tumor subtypes. In multivariate analyses comparing TN to Luminal A, ANX2 was not important while controlling for age and grade. Conclusion: ANX2 might be a biomarker of aggressiveness and a relevant candidate biomarker in high risk African American women with Luminal B and HER2 breast cancer.

Molecular Biomarkers Predict Pathological Complete Response of Neoadjuvant Chemotherapy in Breast Cancer Patients: Review

“…Annexin A2 (ANXA2) is a calcium-binding cytoskeleton protein located on the extracellular surface of endothelial cells and in various types of tumor cells [80]. It has been shown that the expression of ANXA2 in breast tumors can be a biomarker for predicting BC outcome in high-risk groups [81]. Chuthapisith reported that the proteins ANXA1 and ANXA2 are predictors of pCR, as it was demonstrated that the presence of ANXA2 in conjunction with ANXA1 could be a potential marker of non-pCR in BC [70].…”

Molecular and Cellular Factors Associated with Racial Disparity in Breast Cancer

“…Serum-derived exosomes from AA women TNBC patients exhibited higher ANX2 expression compared to those from CA women. ANX2 is associated with the aggressiveness of breast cancer and is considered as a molecular marker for different breast cancer subtypes [ 95 ]. In addition, an overexpressed ANX2 AA cohort was also associated with poor overall survival and poor disease-free survival [ 96 ].…”